Glenmark Pharmaceuticals Limited (Glenmark), a leading research led, global pharmaceutical company, today announced its financial results for the quarter ended June 30, 2024.

For the first quarter of FY25, Glenmark’s consolidated revenue from operations was at Rs. 3,244.2 crore as against Rs. 3,036.1 crore in the corresponding quarter last year, recording overall year-on-year (YoY) growth of 6.9%. EBITDA was at Rs. 588.2 crore in the quarter ended June 30, 2024, with YoY growth of 34.5% and EBITDA margin of 18.1%. The company posted Profit After Tax (PAT) for the quarter ended June 30, 2024 at Rs. 340.2 crore, registering PAT margin of 10.5%.

Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd. said: “Our strong start to the new financial year reflects our robust revenue growth across key regions and solid operational performance, leading to a significantly improved margin profile. Our India business continues to excel, outpacing the Indian Pharma Market with our expertise in our core therapeutic areas, while Europe build on its FY24 success with further growth in the branded segment.

“RYALTRIS remains a major global growth driver, achieving high double-digit market shares in multiple regions. As we look ahead, we are committed to launching innovative products, including Envafolimab and Winlev, and are confident of our trajectory towards meeting our FY25 objectives.”